

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/593,691-Conf. #3128
		Filing Date	December 4, 2006
		First Named Inventor	Ayumu KURIMOTO
		Art Unit	1624
		Examiner Name	M. L. Berch
Sheet	1	of	2
		Attorney Docket Number	0020-5516PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-5,994,361	11-30-1999	Penney et al.	
	AB*	US-6,110,923	08-29-2000	Ely	
	AC*	US-5,736,549	04-07-1998	Beasley et al.	
	AD*	US-7,157,465	01-02-2007	Isobe et al.	
	AE*	US-20030212092	11-13-2003	Heppner et al.	
	AF*	US-20030144283	07-31-2003	Coleman et al.	
	AG*	US-20040019048	01-29-2004	Crooks et al.	
	AH*	US-20040204438	10-14-2004	Crooks et al.	
	AI*	US-20040229897	11-18-2004	Crooks et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	BA	JP-9-347422			
	BB	JP-9-367451			
	BC	JP-9-367449			
	BD	CA-1220148-A1	04-07-1987	Ceskoslovenska Akademie Ved	
	BE	JP-11-180981-A	07-06-1999	Sumitomo Pharma et al.	Abs
	BF	JP-11-180982-A	07-06-1999	Japan Energy Corp et al.	Abs
	BG	JP-2000-159767-A	06-13-2000	Sumitomo Pharma et al.	Abs
	BH	JP-2005-089334-A	04-07-2005	Sumitomo Pharma	Abs
	BI	JP-2004137157A-A	05-13-2004	Sumitomo Pharma	Abs
	BJ	WO-2005025583-A2	03-24-2005	Anadys Pharmaceuticals Inc et al.	
	BK	WO-2004087049-A2	10-14-2004	3m Innovative Properties Co	
	BL	WO-2004075865-A2	09-10-2004	3m Innovative Properties Co	
	BM	WO-0076519-A1	12-21-2000	3m Innovative Properties Co	

Examiner Signature	/Mark Berch/ (03/29/2010)	Date Considered	
-----------------------	---------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with a single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.960(j)(2)(iv)) because that application was filed after June 30, 2003 or is available in the ITW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Application Number		10/593,691-Conf. #3128			
Filing Date		December 4, 2006			
First Named Inventor		Ayumu KURIMOTO			
Art Unit		1624			
Examiner Name		M. L. Berch			
Attorney Docket Number		0020-5516PUS1			
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
CA		Holy, A., et al., "9-(AMINOALKYL)-8-HYDROXYADENINES: PREPARATION, MECHANISM OF FORMATION AND USE IN AFFINITY CHROMATOGRAPHY OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE," Inst. Org. Chem. and Biochem., Czechoslovak Academy of Sciences, Vol. 51, pp 459-477 (1985)		
CB		Kurimoto, A., et al., "Prodrugs of 9-Benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: Potent Interferon Inducing Agents in Monkeys," Chem. Pharm. Bull. Vol 52, No 4, pp 466-469 (2004)		
CC		Krueger, R., et al., "Tilorone Hydrochloride: An Orally Active Antiviral Agent," Science, Vol 169, pp 1213-1214 (1970)		
CD		Mayer, G. D., et al., "Tilorone Hydrochloride: Mode of Action," Science, Vol 169, pp 1214-1215 (1970)		
CE		Nichol, F.R., et al., "Stimulation of Murine Interferon by a Substituted Pyrimidine," Antimicro. Agents and Chemo., Vol 9, No 3, (1976)		
CF		Stringfellow, D. A., et al., "Antiviral and Interferon-Inducing Properties of 1,5-Diamino Anthraquinones," Antimicrobial Agents and Chemo., Vol 15, No 1, pp 111-118, (1979)		
CG		Reiter, M.J., et al., "Cytokine induction in mice by the immunomodulator imiquimod," J. Leukocyte Biol., Vol 55, pp 234-240 (1994)		
CH		Lee, J., et al., "Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7," PNAS, Vol 100, No 11, pp 6646-6651 (2003)		
CI		Isobe, Y., et al., "Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers," J. Med. Chem., Vol 49, No 6, pp 2088-2095 (2006)		
CJ		USPTO Office Action issue 4/8/2009 in application no 10/594,074		
CK		USPTO Office Action issue 7/8/2009 in application no 10/594,074		
CL		USPTO Office Action issue 10/13/2009 in application no 12/066,952		

Examiner Signature	/Mark Berch/ (03/29/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> CITE NO.: These application(s) which are marked with a single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the F.W. <sup>3</sup> Applicant's unique citation designation number (optional). <sup>4</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>5</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>7</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.